ZVSA vs. SNGX, GTBP, EVOK, SEEL, THAR, LGVN, GNPX, ENSC, DRUG, and ARTL
Should you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Soligenix (SNGX), GT Biopharma (GTBP), Evoke Pharma (EVOK), Seelos Therapeutics (SEEL), Tharimmune (THAR), Longeveron (LGVN), Genprex (GNPX), Ensysce Biosciences (ENSC), Bright Minds Biosciences (DRUG), and Artelo Biosciences (ARTL). These companies are all part of the "pharmaceutical preparations" industry.
ZyVersa Therapeutics (NASDAQ:ZVSA) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.
ZyVersa Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.
ZyVersa Therapeutics currently has a consensus price target of $120.00, suggesting a potential upside of 1,848.05%. Soligenix has a consensus price target of $3.00, suggesting a potential upside of 631.71%. Given ZyVersa Therapeutics' higher possible upside, research analysts plainly believe ZyVersa Therapeutics is more favorable than Soligenix.
Soligenix received 275 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 72.97% of users gave Soligenix an outperform vote.
3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 0.7% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 1.4% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Soligenix has higher revenue and earnings than ZyVersa Therapeutics.
In the previous week, Soligenix had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for Soligenix and 0 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.00 equaled Soligenix'saverage media sentiment score.
ZyVersa Therapeutics has a net margin of 0.00% compared to Soligenix's net margin of -731.94%. ZyVersa Therapeutics' return on equity of -233.62% beat Soligenix's return on equity.
Summary
Soligenix beats ZyVersa Therapeutics on 7 of the 13 factors compared between the two stocks.
Get ZyVersa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZyVersa Therapeutics Competitors List
Related Companies and Tools
